Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency
Status:
Unknown status
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Icotinib is efficient and safe in treating
advanced non-small cell lung cancer (NSCLC) patients with hepatic insufficiency.